Literature DB >> 16288224

HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells.

M Natarajan1, J E Stewart, E A Golemis, E N Pugacheva, K Alexandropoulos, B D Cox, W Wang, J R Grammer, C L Gladson.   

Abstract

The highly invasive behavior of glioblastoma cells contributes to the morbidity and mortality associated with these tumors. The integrin-mediated adhesion and migration of glioblastoma cells on brain matrix proteins is enhanced by stimulation with growth factors, including platelet-derived growth factor (PDGF). As focal adhesion kinase (FAK), a nonreceptor cytoplasmic tyrosine kinase, has been shown to promote cell migration in various other cell types, we analysed its role in glioblastoma cell migration. Forced overexpression of FAK in serum-starved glioblastoma cells plated on recombinant (rec)-osteopontin resulted in a twofold enhancement of basal migration and a ninefold enhancement of PDGF-BB-stimulated migration. Both expression of mutant FAK(397F) and the downregulation of FAK with small interfering (si) RNA inhibited basal and PDGF-stimulated migration. FAK overexpression and PDGF stimulation was found to increase the phosphorylation of the Crk-associated substrate (CAS) family member human enhancer of filamentation 1 (HEF1), but not p130CAS or Src-interacting protein (Sin)/Efs, although the levels of expression of these proteins was similar. Moreover downregulation of HEF1 with siRNA, but not p130CAS, inhibited basal and PDGF-stimulated migration. The phosphorylated HEF1 colocalized with vinculin and was associated almost exclusively with 0.1% Triton X-100 insoluble material, consistent with its signaling at focal adhesions. FAK overexpression promoted invasion through normal brain homogenate and siHEF1 inhibited this invasion. Results presented here suggest that HEF1 acts as a necessary and specific downstream effector of FAK in the invasive behavior of glioblastoma cells and may be an effective target for treatment of these tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16288224     DOI: 10.1038/sj.onc.1209199

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  95 in total

1.  Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells.

Authors:  Sun-Hee Kim; Dianren Xia; Sang-Wook Kim; Vijaykumar Holla; David G Menter; Raymond N Dubois
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

2.  NEDD9 depletion leads to MMP14 inactivation by TIMP2 and prevents invasion and metastasis.

Authors:  Sarah L McLaughlin; Ryan J Ice; Anuradha Rajulapati; Polina Y Kozyulina; Ryan H Livengood; Varvara K Kozyreva; Yuriy V Loskutov; Mark V Culp; Scott A Weed; Alexey V Ivanov; Elena N Pugacheva
Journal:  Mol Cancer Res       Date:  2013-11-07       Impact factor: 5.852

Review 3.  Biology of angiogenesis and invasion in glioma.

Authors:  Matthew C Tate; Manish K Aghi
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

4.  Downregulation of NEDD9 by apigenin suppresses migration, invasion, and metastasis of colorectal cancer cells.

Authors:  Jin Dai; Peter G Van Wie; Leonard Yenwong Fai; Donghern Kim; Lei Wang; Pratheeshkumar Poyil; Jia Luo; Zhuo Zhang
Journal:  Toxicol Appl Pharmacol       Date:  2016-09-20       Impact factor: 4.219

Review 5.  Cell migration and metastasis markers as targets of environmental pollutants and the Aryl hydrocarbon receptor.

Authors:  Robert Barouki; Xavier Coumoul
Journal:  Cell Adh Migr       Date:  2010-01-05       Impact factor: 3.405

6.  NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer.

Authors:  Yann Wallez; Peter D Mace; Elena B Pasquale; Stefan J Riedl
Journal:  Genes Cancer       Date:  2012-05

Review 7.  Cell cycle-dependent ciliogenesis and cancer.

Authors:  Olga V Plotnikova; Erica A Golemis; Elena N Pugacheva
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance.

Authors:  Yu-Zheng Xue; Ying-Yue Sheng; Zong-Liang Liu; Zhe-Qiang Wei; Hai-Yan Cao; Yan-Min Wu; Yu-Feng Lu; Li-Hua Yu; Jian-Ping Li; Zhao-Shen Li
Journal:  Tumour Biol       Date:  2012-12-18

9.  Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Authors:  Vita M Golubovskaya; Grace Huang; Baotran Ho; Michael Yemma; Carl D Morrison; Jisook Lee; Brian P Eliceiri; William G Cance
Journal:  Mol Cancer Ther       Date:  2012-12-12       Impact factor: 6.261

10.  NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma.

Authors:  Rongfeng Shi; Lei Wang; Tao Wang; Junfei Xu; Feiran Wang; Meirong Xu
Journal:  Med Oncol       Date:  2014-01-28       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.